Effects of Metoclopramide and Ondansetron on Post-Cesarean Nausea and Vomiting

A Comparison of the Efficacy of Metoclopramide and Ondansetron in Reducing Nausea and Vomiting during Spinal Anesthesia for Elective Cesarean Section

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260425069157N1

Enrollment

140

Registered

2026-04-28

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective cesarean section. Encounter for cesarean delivery without indication

Interventions

Intervention 1: Ten milligrams of injectable metoclopramide (10 mg/2 mL ampoule, Sina Darou Pharmaceutical Co., Iran) diluted with normal saline to a final volume of 5 mL will be administered intraven

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age 18–40 years Willingness to participate and providing informed consent Singleton pregnancy undergoing elective cesarean section ASA physical status class I–II

Exclusion criteria

Exclusion criteria: Withdrawal of consent at any stage of the study Known hypersensitivity to metoclopramide, ondansetron, or any component of their formulations Development of drug-related adverse effects

Design outcomes

Primary

Measure	Time frame
Incidence and frequency of nausea and vomiting following the intervention. Timepoint: 0–1 hour after intervention,1–2 hours after intervention,2–4 hours after intervention,4–6 hours after intervention. Method of measurement: The incidence of nausea and vomiting will be recorded as dichotomous variables (Yes/No). In addition, the frequency (number of episodes) of nausea and vomiting will be documented during the following postoperative time intervals:.	—

Measure

Time frame

Incidence and frequency of nausea and vomiting following the intervention. Timepoint: 0–1 hour after intervention,1–2 hours after intervention,2–4 hours after intervention,4–6 hours after intervention. Method of measurement: The incidence of nausea and vomiting will be recorded as dichotomous variables (Yes/No). In addition, the frequency (number of episodes) of nausea and vomiting will be documented during the following postoperative time intervals:.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Roghayea Neisari

Oroumia University of Medical Sciences

nisari.r@umsu.ac.ir+98 44 3346 0998

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026